Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | +1.61% | +22.73% | +48.82% |
03:20pm | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
16/05 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.82% | 12.05M | |
+42.42% | 54.04B | |
+43.57% | 41.96B | |
-1.42% | 41.92B | |
-7.59% | 28.35B | |
+11.35% | 26.35B | |
-22.10% | 19B | |
+7.43% | 13B | |
+28.35% | 12.28B | |
+25.52% | 12.19B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Reports Q3 Revenue $79.6M